About: A Neuroprotective Dose of Isatin Causes Multilevel Changes Involving the Brain Proteome: Prospects for Further Research

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A Neuroprotective Dose of Isatin Causes Multilevel Changes Involving the Brain Proteome: Prospects for Further Research Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	A Neuroprotective Dose of Isatin Causes Multilevel Changes Involving the Brain Proteome: Prospects for Further Research
Creator	Buneeva, Olga Medvedev, Alexei Ivanov, Alexis Kopylov, Arthur Kurbatov, Leonid Tikhonova, Olga Zgoda, Victor
Source	PMC
abstract	Isatin (indole-2,3-dione) is an endogenous regulator, exhibiting a wide range of biological and pharmacological activities. At doses of 100 mg/kg and above, isatin is neuroprotective in different experimental models of neurodegeneration. Good evidence exists that its effects are realized via interaction with numerous isatin-binding proteins identified in the brain and peripheral tissues studied. In this study, we investigated the effect of a single dose administration of isatin to mice (100 mg/kg, 24 h) on differentially expressed proteins and a profile of the isatin-binding proteins in brain hemispheres. Isatin administration to mice caused downregulation of 31 proteins. However, these changes cannot be attributed to altered expression of corresponding genes. Although at this time point isatin influenced the expression of more than 850 genes in brain hemispheres (including 433 upregulated and 418 downregulated genes), none of them could account for the changes in the differentially expressed proteins. Comparative proteomic analysis of brain isatin-binding proteins of control and isatin-treated mice revealed representative groups of proteins sensitive to isatin administration. Control-specific proteins (n = 55) represent specific targets that interact directly with isatin. Appearance of brain isatin-binding proteins specific to isatin-treated mice (n = 94) may be attributed to the formation of new clusters of protein–protein interactions and/or novel binding sites induced by a high concentration of this regulator (ligand-induced binding sites). Thus, isatin administration produces multiple effects in the brain, which include changes in gene expression and also profiles of isatin-binding proteins and their interactomes. Further studies are needed for deeper insight into the mechanisms of the multilevel changes in the brain proteome induced by isatin. In the context of the neuroprotective action, these changes may be aimed at interruption of pathological links that begin to form after initiation of pathological processes.
has issue date	2020-06-11(xsd:dateTime)
bibo:doi	10.3390/ijms21114187
bibo:pmid	32545384
has license	cc-by
sha1sum (hex)	fb0e65a2675f64864d05cd44b0bd166bcea2dbec
schema:url	https://doi.org/10.3390/ijms21114187
resource representing a document's title	A Neuroprotective Dose of Isatin Causes Multilevel Changes Involving the Brain Proteome: Prospects for Further Research
has PubMed Central identifier	PMC7313464
has PubMed identifier	32545384
schema:publication	Int J Mol Sci
resource representing a document's body	covid:fb0e65a2675f64864d05cd44b0bd166bcea2dbec#body_text
is schema:about of	covid:arg/fb0e65a2675f64864d05cd44b0bd166bcea2dbec named entity 'isatin' named entity 'mice' named entity 'mice' named entity 'ligand' named entity 'Isatin' named entity 'neurodegeneration' named entity 'proteome' named entity 'pharmacological activities' named entity 'differentially expressed' named entity 'isatin' named entity 'interact' named entity 'endogenous' named entity 'Isatin' named entity 'downregulation' named entity 'brain hemispheres' named entity 'isatin' named entity 'ppm' named entity 'p53' named entity 'binding activity' named entity 'thymopoietin' named entity 'oxidized' named entity 'Charcot-Marie-Tooth disease' named entity 'cysteine' named entity 'brain hemispheres' named entity 'isatin' named entity 'Cy3' named entity 'neuroprotective' named entity 'formic acid' named entity 'transcription' named entity 'synapse' named entity 'affinity ligand' named entity 'Agilent' named entity 'isatin' named entity 'RNA' named entity 'GUI' named entity 'isatin' named entity 'isatin' named entity 'mice' named entity 'body fluids' named entity 'Chromatographic separation' named entity 'transcription' named entity 'microtubules' named entity 'ribosome' named entity 'antioxidant' named entity 'endogenous' named entity 'protein-protein interactions' named entity 'neurotoxin' named entity 'protein' named entity 'TGF-β signaling' named entity 'data processing' named entity 'PTK2' named entity 'transcription' named entity 'antibacterial' named entity 'protein' named entity 'macromolecule' named entity '2.1' named entity 'activation energy' named entity 'mice' named entity 'protein binding' named entity 'cell proliferation' named entity 'proteasomes' named entity 'proteomic' named entity 'FAK' named entity 'cytoskeleton' named entity 'glycolytic enzyme' named entity 'RNA' named entity 'mice' named entity 'action potential' named entity 'transcriptomic' named entity 'isatin' named entity 'neuroprotective' named entity 'mice' named entity 'fructose-1,6-bisphosphatase 1' named entity 'Biological activities'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software